Logo
x

Search

Subscribe Now

myelofibrosis

AstraZeneca Signs an Exclusive License Agreement with Sierra for AZD5153 to Treat Myelofibrosis

AstraZeneca Signs an Exclusive License Agreement with Sierra for AZD5153 to Treat Myelofibrosis

  • August 6, 2021
BMS' Inrebic (fedratinib) Receives EC's Approval for Patients with Newly Diagnosed and Previously Treated Myelofibrosis

BMS' Inrebic (fedratinib) Receives EC's Approval for Patients with Newly Diagnosed and Previously Treated Myelofibrosis

  • February 9, 2021
Incyte Collaborates with Cellenkos for CK0804 to Treat Myelofibrosis

Incyte Collaborates with Cellenkos for CK0804 to Treat Myelofibrosis

  • December 31, 2020
BMS' Inrebic (fedratinib) Receives Health Canada's Approval for Patients with Myelofibrosis

BMS' Inrebic (fedratinib) Receives Health Canada's Approval for Patients with Myelofibrosis

  • September 22, 2020
Celgene's Inrebic (fedratinib) Receives the US FDA's Approval for Myelofibrosis

Celgene's Inrebic (fedratinib) Receives the US FDA's Approval for Myelofibrosis

  • August 19, 2019
Celgene's Fedratinib Receives FDA's Priority Review to NDA Filing for Myelofibrosis

Celgene's Fedratinib Receives FDA's Priority Review to NDA Filing for Myelofibrosis

  • March 6, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.